Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5846241 | Toxicology and Applied Pharmacology | 2014 | 8 Pages |
Abstract
Clinical studies have demonstrated that conditionally replicating adenovirus is safe. We constructed an oncolytic adenovirus, Ad-hTERT-E1a-Apoptin, using a cancer-specific promoter (human telomerase reverse transcriptase promoter, hTERTp) and a cancer cell-selective apoptosis-inducing gene (Apoptin). Ad-hTERT-E1a-Apoptin was proven effective both in vitro and in vivo in our previous study. In this study, the preclinical safety profiles of Ad-hTERT-E1a-Apoptin in animal models were investigated. At doses of 5.0 Ã 108, 2.5 Ã 109, and 1.25 Ã 1010 viral particles (VP)/kg, Ad-hTERT-E1a-Apoptin had no adverse effects on mouse behavior, muscle cooperation, sedative effect, digestive system, and nervous systems, or on beagle cardiovascular and respiratory systems at 5.0 Ã 108, 2.5 Ã 109, and 1.25 Ã 1010 VP/kg doses. In acute toxicity tests in mice, the maximum tolerated dose > 5 Ã 1010 VP/kg. There was no inflammation or ulceration at the injection sites within two weeks. In repeat-dose toxicological studies, the no observable adverse effect levels of Ad-hTERT-E1a-Apoptin in rats (1.25 Ã 1010 VP/kg) and beagles (2.5 Ã 109 VP/kg) were 62.5- and 12.5-fold of the proposed clinical dose, respectively. The anti-virus antibody was produced in animal sera. Bone marrow examination revealed no histopathological changes. Guinea pigs sensitized by three repeated intraperitoneal injections of 1.35 Ã 1010 VP/mL Ad-hTERT-E1a-Apoptin each and challenged by one intravenous injection of 1.67 Ã 108 VP/kg Ad-hTERT-E1a-Apoptin did not exhibit any sign of systemic anaphylaxis. Our data from different animal models suggest that Ad-hTERT-E1a-Apoptin is a safe anti-tumor therapeutic agent.
Keywords
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Yanxin Qi, Huanhuan Guo, Ningning Hu, Dongyun He, Shi Zhang, Yunjie Chu, Yubin Huang, Xiao Li, LiLi Sun, Ningyi Jin,